Stem Cells International / 2021 / Article / Tab 1

Review Article

Characteristics and Developments in Mesenchymal Stem Cell Therapy for COVID-19: An Update

Table 1

Clinical trials investigated the use of MSCs for COVID-19 treatment marked “completed” on clinicaltrials.gov.

Trial ID no.StatusResponsible countryStudy titleInterventions

NCT04288102CompletedChinaTreatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19)UC-MSCs
NCT04355728CompletedUnited StatesUse of UC-MSCs for COVID-19 patientsUC-MSCs
NCT04492501CompletedPakistanInvestigational treatments for COVID-19 in tertiary care hospital of PakistanMSCs
NCT04522986CompletedJapanAn exploratory study of ADR-001 in patients with severe pneumonia caused by SARS-CoV-2 infection (COVID-19)AD-MSCs
NCT04535856CompletedIndonesiaTherapeutic study to evaluate the safety and efficacy of DW-MSC in COVID-19 patients (DW-MSC)MSCs
NCT04573270CompletedUnited StatesMesenchymal stem cells for the treatment of COVID-19UC-MSCs
NCT04713878CompletedTurkeyMesenchymal stem cells therapy in patients with COVID-19 pneumoniaMSCs

UC-MSCs: human umbilical cord mesenchymal stem cells; AD-MSCs: adipose-derived mesenchymal stem cells.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.